Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Cannon

Showing results (901-910 of 934) with videos related to

Pageof 94
Sort By:
Journal of the American College of Cardiology|August 12, 2017
Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary DiseaseDaniel Lindholm, Johan Lindbäck, Paul W Armstrong, et al.
American Heart Journal|June 18, 2018
High-dose influenza vaccine to reduce clinical outcomes in high-risk cardiovascular patients: Rationale and design of the INVESTED trialOrly Vardeny, Jacob A Udell, Jacob Joseph, et al.
JAMA|June 23, 2011
Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysisDavid Preiss, Sreenivasa Rao Kondapally Seshasai, Paul Welsh, et al.
JAMA|October 28, 2010
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysisJessica L Mega, Tabassome Simon, Jean-Philippe Collet, et al.
American Heart Journal|December 25, 2015
High-degree atrioventricular block, asystole, and electro-mechanical dissociation complicating non-ST-segment elevation myocardial infarctionSean D Pokorney, Christina Radder, Phillip J Schulte, et al.
Circulation. Heart Failure|January 22, 2026
Association Between the 2022 AHA/ACC/HFSA Heart Failure Staging and Cardiovascular and Kidney Outcomes in Patients With Diabetes and Kidney Disease: A Post Hoc Analysis of the SCORED Randomized Controlled TrialAyodele Odutayo, Deepak L Bhatt, Vikas S Sridhar, et al.
The American Journal of Geriatric Cardiology|June 21, 2001
Executive Summary: Pivotal Research in Cardiovascular Syndromes in the ElderlyCharles R. McKay, Michael W. Rich, Ronald E. Vlietstra, et al.
American Journal of Nephrology|December 19, 2017
The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline CharacteristicsMeg J Jardine, Kenneth W Mahaffey, Bruce Neal, et al.
Journal of the American College of Cardiology|February 25, 2014
Ticagrelor effects on myocardial infarction and the impact of event adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) trialKenneth W Mahaffey, Claes Held, Daniel M Wojdyla, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|March 8, 2023
Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical TrialTae Won Yi, Brendan Smyth, Gian Luca Di Tanna, et al.
Pageof 94

Showing results (901-910 of 934) with videos related to

Sort By:
Pageof 94
Journal of the American College of Cardiology|August 12, 2017
Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary DiseaseDaniel Lindholm, Johan Lindbäck, Paul W Armstrong, et al.
American Heart Journal|June 18, 2018
High-dose influenza vaccine to reduce clinical outcomes in high-risk cardiovascular patients: Rationale and design of the INVESTED trialOrly Vardeny, Jacob A Udell, Jacob Joseph, et al.
JAMA|June 23, 2011
Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysisDavid Preiss, Sreenivasa Rao Kondapally Seshasai, Paul Welsh, et al.
JAMA|October 28, 2010
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysisJessica L Mega, Tabassome Simon, Jean-Philippe Collet, et al.
American Heart Journal|December 25, 2015
High-degree atrioventricular block, asystole, and electro-mechanical dissociation complicating non-ST-segment elevation myocardial infarctionSean D Pokorney, Christina Radder, Phillip J Schulte, et al.
Circulation. Heart Failure|January 22, 2026
Association Between the 2022 AHA/ACC/HFSA Heart Failure Staging and Cardiovascular and Kidney Outcomes in Patients With Diabetes and Kidney Disease: A Post Hoc Analysis of the SCORED Randomized Controlled TrialAyodele Odutayo, Deepak L Bhatt, Vikas S Sridhar, et al.
The American Journal of Geriatric Cardiology|June 21, 2001
Executive Summary: Pivotal Research in Cardiovascular Syndromes in the ElderlyCharles R. McKay, Michael W. Rich, Ronald E. Vlietstra, et al.
American Journal of Nephrology|December 19, 2017
The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline CharacteristicsMeg J Jardine, Kenneth W Mahaffey, Bruce Neal, et al.
Journal of the American College of Cardiology|February 25, 2014
Ticagrelor effects on myocardial infarction and the impact of event adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) trialKenneth W Mahaffey, Claes Held, Daniel M Wojdyla, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|March 8, 2023
Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical TrialTae Won Yi, Brendan Smyth, Gian Luca Di Tanna, et al.
Pageof 94